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Abstract 
Aplastic anemia (AA) is a rare hematopoietic disease characterized by a pancytopenia and a 
hypoplastic bone marrow. AA can be congenital (CAA) or acquired (AAA). Acquired AA 
comprises those cases where a causative factor is identified (Secondary AA) and also 
idiopathic cases (Idiopathic AA). There was a marked improvement on treatment options in 
the last years that had resulted on increased overall survival rates. It is known that a correct 
management of this entity is directly related with an efficient diagnostic investigation, and for 
that, it is fundamental to be aware of the most effective strategies or techniques available 
nowadays.   
Therefore, the aim of this review is to make a state of art of the most recent available data 
concerning this disorder, particularly IAA, including all the sub-topics inherent: etiology, 
pathophysiology mechanisms, differential diagnosis, management and treatment options.  
 
 
Key-words: Aplastic Anemia, Idiopathic Aplastic Anemia, Congenital Aplastic Anemia,  
Autoimmunity, Hypocellular Bone Marrow, Pancytopenia, Immunosuppressive therapy, 
Hematopoietic Stem Cell Transplantation, Paroxysmal Nocturnal Hemoglobinuria.   
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Resumo 
A Anemia Aplásica (AA) é uma doença hematopoiética rara caracterizada por pancitopenia e 
hipocelularidade da medula óssea. A AA pode ser congénita ou adquirida.  A AA Adquirida 
inclui os casos em que é possível identificar um fator causal (AA Secundária) e também os 
casos idiopáticos (AA Idiopática). Nos últimos anos tem havido uma melhoria notável nas 
opções de tratamento o que tem conduzido  a melhores taxas de sobrevivência.  É também um 
facto estabelecido que uma orientação clínica correta está diretamente relacionada com uma 
investigação diagnóstica eficiente, o que por sua vez exige um conhecimento sobre as 
estratégias e técnicas mais eficazes disponíveis na atualidade. 
O objetivo desta revisão é fazer um estado da arte das publicações e dados mais recentes 
relacionados com esta doença, especificamente em relação à Anemia Aplásica Idiopática, 
incluindo assim todos os subtópicos inerentes: etiologia, mecanismos fisiopatológicos, 
diagnóstico diferencial, conduta e opções de tratamento.  
 
 
Palavras-chave: Anemia Aplásica, Anemia Aplásica Idiopática, Anemia Aplásica Congénita, 
Auto-imunidade, Medula Óssea Hipocelular, Pancitopenia, Terapia Imunossupressora, 
Transplante de células estaminais  hematopoiéticas, Hemoglobinúria Nocturna Paroxística.   
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Abbreviations  
AA - Aplastic Anemia 
AAA - Acquired Aplastic Anemia 
AL - Acute Leukemia 
ALL - Acute Lymphoblastic Leukemia  
ALZ - Alemtuzumab  
AML - Acute Myeloid Leukemia  
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G-CSF - Granulocyte Colony-Stimulating Factor  
GPI - Glycosylphosphatidylinositol 
GVHD - Graft-Versus-Host Disease  
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MDS- Myelodysplastic Syndromes  
MMC - Mitomycin C  
MRI - Magnetic Resonance Imaging  
NIH - National Institutes of Health (U.S. Department of Health and Human Services) 
N-SAA – Non Severe Aplastic Anemia 
OS - Overall Survival  
PNH - Paroxysmal Nocturnal Hemoglobinuria  
r-ATG - Rabbit Antithymocyte Globulin 
SAA – Severe Aplastic Anemia 
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Introduction 
Aplastic Anemia (AA) is a singular hematological rare disease that combines a blood 
pancytopenia with a hypocellular bone marrow (BM) – the simplicity of these criteria 
conferred this clinical condition a reference as the paradigm of BM failure syndromes.
1
  
AA can be congenital or acquired. Congenital AA (CAA) comprise the inherited disorders of 
BM failure that usually presents in the first years of life, being also associated with one or 
more somatic abnormalities. Acquired AA (AAA) includes the impaired hematopoiesis that 
can result from secondary causes (like exposure to toxics, drugs, radiation and virus) or it can 
be idiopathic, where the causative agent is unknown. 
Idiopathic AA (IAA) is the aim of this review. Several studies reports that it is an immune-
mediated disease, characterized by a T-cell-mediated organ specific destruction of BM 
hematopoietic cells – and several questions had been introduced since the description of the 
first case by Ehrlich in 1888: what leads to the immune response against hematopoietic stem 
cells? Is there any risk factor- environmental or genetic? Can we change the clinical outcome? 
Why some clear associations with other diseases, like Paroxysmal Nocturnal 
Hemoglobinuria (PNH) or Myelodysplastic Syndromes (MDS)? What can we offer to the 
patients?  
Some old questions remain unanswered, and the improvement in cellular and biological 
research combined with the advances on investigation methods lead to new questions, 
providing a wide collection of publications regarding this clinical entity. Research works are 
therefore fundamental to the development of more accurate differential diagnostic algorithms 
(which include phenotypic, clinical laboratory and genetic data) or the most effective 
treatment options.    
In fact, the differential diagnosis should be taken as one crucial step, being the main key of a 
successful treatment. For example, the presence of a fatty BM on biopsy indicates aplasia; 
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however, marrow hypocellularity, and the correspondent degree of cytopenias, can occur in 
several others hematologic diseases. Time between the establishment of a diagnosis and the 
beginning of treatment is also crucial since it is directly related to outcome regardless of the 
therapeutic option chosen. 
The goal of this review is to make a state of art of this disorder – and therefore, line up a 
working method. In the presence of a potential case of IAA is fundamental to know what 
others diseases should be ruled out, which are the best treatment options and what are the 
possible outcomes. Considering that a correct management is only possible with a correct 
understanding of the disease, all the remaining sub-items inherent (such as incidence or 
pathophysiology) will also be explored. 
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1- Incidence of Acquired Aplastic Anemia 
AAA had been the target of several epidemiologic studies – however, the most recent remains 
a prospective multicenter study between 1980 and 2003, in the metropolitan area of 
Barcelona
2
. This study shows an overall incidence of AA of 2,34 cases per million per year, 
which is reported to be similar to data reported on other population-based studies which had 
taken place in different Western countries (European countries such as France and United 
Kingdom, and also Israel and Brazil). Asian data and studies shows different incidence rates, 
being reported as two to three folds higher.
3 
This
 
dissemblance is observed and related in 
several epidemiologic studies. It is supported by different studies that use the same 
methodology, in opposition to some historical literature that report larger differences between 
Western and East. These differences are currently considered as exaggerated, and can be 
explained considering the absence of some diagnostic tools (e.g. the use of marrow biopsies 
for the AA diagnosis instead of only consider blood counts)
1
.   
The marked difference between these two global areas (European countries and Asian 
countries) remains unexplained.
4 
However, and without any other recent data, this geographic 
difference between East and West is currently accepted. 
The largest studies such as Barcelona
2
 also reports a sex ratio close to 1:1, and two patient age 
peaks of incidence, translating a biphasic age distribution: one peak among young adults (15-
25 years old) and a second peak in the elderly (≥65 years old). 
Due the lacking of a clear division in all studies between the cases of Secondary AA and the 
IAA cases, these incidence data are referent to AAA - the cases diagnosed as CAA were 
excluded and correctly defined as one exclusion criteria in all the mentioned articles.  
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2- Pathophysiology  
IAA is an immune-mediated disease? 
AA is characterized by pancytopenia with a hypocellular BM, caused by the decrease of 
hematopoietic cells. Hematopoietic stem cells (CD34+) [u1]are markedly diminished, and it is 
reported a reduction on stem cell pool to 1% of normal at the time of presentation in in vitro 
assays.
8  
Literature also refers a predominance of fat tissue, which is believed to result from 
the replacement of the BM cells.
8
  
Any attempts to establish a clear knowledge about the pathological mechanisms involved in 
AAA are hampered by its nature – it’s a rare disorder, as seen by the epidemiological data, as 
well as a result of its characteristics, namely pancytopenia and hypocellular BM. Therefore, 
the possible cells of interest had 
disappeared, increasing 
substantially all the hindrances of 
achieving satisfactory answers.  
Etiology was firstly linked to 
possible relationships of AA to 
environmental factors – like 
chemicals and medical drug 
exposures - or to some clinical 
associations with conditions like 
pregnancy, seronegative hepatitis 
or syndromes like eosinophilic 
fasciitis. A full list of some 
etiologic agents of AAA can be 
seen in Table 1.  
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However, even that some relationships appears to be real, it is also reported that neither 
chemicals or drugs appear to be responsible for the majority of cases and no satisfactory 
mechanisms were infered.
1
  
Nowadays, literature leads us to separate the cases where a triggering condition can be linked, 
and label it as Secondary AA, from those where a causative agent is unknown, being this 
classified as Idiopathic AA. 
Idiopathic AA is reported as one pathologic entity linked to an immune mechanism. 
Considering both the oldest and current reports a major conclusion can arise: even that there 
are plenty of laboratory data supporting an immune pathophysiology, concrete information 
about detailed mechanisms are still lacking.
9  
Therefore there are plenty factors believed to be involved in the immune attack, and this 
immune-mediated disease is widely reported to be a result of several particular roles 
concretized by each one of them. Considering the latest reports, it is now presented a 
summary of those most widely referred on current literature, namely the role of lymphocytes, 
cytokines, autoantibodies and genetic factors.  
 
2.1 – Lymphocytes 
Lymphocytes T are widely reported as having a major role in the BM destruction. In 2006, 
Young published a wide compilation about the pathophysiologic mechanisms in AAA
1
.  The 
author reports that the effector cells of the BM destruction phenomena were the activated 
cytotoxic T cells (CTL). He also explains that this conclusion resulted from the observation of 
the improvement of aplastic BMs after removal of lymphocytes and the inhibition of 
hematopoiesis after their addition to normal BMs in vitro, allied with the identification by 
immunophenotyping techniques. 
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CTL express Th1 cytokines. Th1 cytokines are the responsible for the production of the pro-
inflammatory responses necessary to destroy intracellular parasites and for perpetuating 
autoimmune responses (see section 2.2).
10
  
Young also presented the concept of the oligoclonal expansion of CD8+ CD28- cells in AA 
patients. The author explained that these clones can be identified by flow cytometry analysis 
of T cell receptor (TCR) Vβ subfamilies – the method includes spectratyping technology, to 
detect skewing of CDR3 length and in the end, sequencing the CDR3 region to establish a 
molecular clonotype
1
.  The author reported that the use of these techniques in AA cases 
allowed the detection of oligoclonal expansions of a few Vβ subfamilies in patients at the 
time of clinical presentation. It is also mentioned that these same clones diminish or disappear 
after successful therapy. Therefore, it can be related with the course of the disease by itself, as 
explained in the Treatment section (section 6) in this document.  
The oligoclonal expansion is widely explored in the later publications from different authors 
and a 2014 review
13
 by Dolberg & Levy presented the main conclusion:  the finding of these 
T cell subpopulation supports the hypothesis that one of the mechanisms of AA is an antigen-
specific lymphocyte attack against hematopoietic tissue.
13 
 
2.2- Cytokines 
CTL express Th1 cytokines and these play a major role in the development of BM failure. 
Interferon gamma (INF-γ) is the main Th1 cytokine. The role of INF-γ is also explored by the 
work of Young (2006) which explained that after using microarray of the scant CD34+ cells 
from marrow failure patients it was possible to reveal a transcriptome in which genes 
involved in apoptosis, cell death, and immune regulation were upregulated.  It is also stated 
that this transcriptional signature can be reproduced in normal CD34+ cells exposed to INF-
γ.1    
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It is also reported that IFN-γ gene expression is specifically prevalent in the BM of patients 
with IAA, and disappears with response to immunosuppression.
13
 
One of the most mentioned apoptotic ways is the increased expression of FAS antigen on BM 
CD34+ cells of patients – this FAS antigen is described as being one receptor molecule that 
mediates signals for programmed cell death. It is enhanced by INF-γ, leading to a hypoplastic 
BM induction.
13  
Tumor necrosis factor gamma (TNF-α), another Th1 cytokine, is also reported to be related to 
this apoptotic way, having a similar role to that of IFN-γ.13  
Besides INF-γ and TNF-α, some other cytokines had been identified and mentioned in 
literature: IL-17, which is secreted from TH17 cells (a subset of T helper cells), is also a Th1 
cytokine and  it is stated that the expression of this cytokine is increased in patients with 
AA.
13
 IL-27 is reported to have an immune regulatory function – it can activate the T-bet[u2] 
transcription (see section 4.2.2), Th1 differentiation can also induce initial CD4+ T cells to 
differentiate into Th1 cells promoting Th1-type immune responses. Like IL-17, IL-27 levels, 
are also reported to be increased in IAA patients.
13 
 
2.3- Autoantibodies 
Some autoantibodies were associated with AA. Nakao et al (2005) explored extensively two 
of them: antibodies to kinectin and antibodies to diazepam-binding inhibitor–related sequence 
1 (DRS-1).
12
 Kinectin is one of the most mentioned in literature. Kinectin is a protein only 
expressed by a reduced number of human tissues which includes the liver, the brain, the testis, 
and also BM CD34+ cells.  DRS-1 protein is highly expressed by CD34+ cells from healthy 
individuals. Antibodies directed to each protein were detected in some AA patients in contrast 
to their absence on healthy individuals. 
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Autoantibodies to the hematopoietic cell line K562 and to the BM stromal cell line hTS-5 are 
also mentioned by Dolberg & Levy (2014) as being correlated with IAA.
13 
 
2.4 – Genetic Factors 
Some host genetic characteristics were identified and are currently associated with a higher 
susceptibility of IAA, as Human Leucocyte Antigen (HLA), T-Cell encoding genes, . 
cytokines polymorphisms and telomeres. 
  
2.4.1-   Human Leukocyte Antigen (HLA) 
HLA-DR2 is widely associated with susceptibility to IAA - it was demonstrated and reported 
that there was an overrepresentation of DR2 in AA patients when compared with their 
siblings and parents
14
. HLA-DR2 has been split into DR15 and DR16, and it was also 
demonstrated that susceptibility could be attributed to DR 15 but not DR 16.
15 
 
Nakao et al (2005) also stated that the frequency of HLA-DR15 is significantly higher in AA 
patients when compared with healthy control populations
 
and the frequency of this allele is 
also particularly high in Japanese adult patients with IAA aged with more than 40 years old.
12 
HLA association in children has been reported as inconsistent, which may lead to the 
hypothesis of different causative factors for AA in children from those in the older age 
groups.
14
 
 
 
2.4.2 – T-Cell Encoding Genes 
T-bet gene belongs to the T-box family of transcription factors, and it is the key regulator of 
Th1 development and function.
13
 It is reported to be found in Th1 but not in Th2 cells.
13
 
It was presented by Bacigalupo in 2007 that CD4
+ 
CD25
+ 
FOXP3
+
 regulatory T cells are 
deficient in IAA patients, and this deficient regulation of T cells could then lead to an increase 
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of T-bet protein levels, increasing INF-γ (T-bet transcribes actively the IFN-γ gene) leading, 
as seen, to stem cell destruction.
6 
 
2.4.3 – STAT3 Acquired Mutations 
A recent publication by Young from 2013
9
 introduces some new concepts to those already 
explored in older publications – the author refers the possible role of acquired mutations in 
STAT3 in AA patients. These mutations would functionally result in constitutive activation of 
this signal transducer; Young also states that acquired STAT3 mutations had been reported in 
others pathological situations like autoimmune diseases. They are also prevalent in Large 
Granular Lymphocyte Leukemia (LGLL), a clinical entity in which a single T-cell clone 
dominates and suppresses BM function.
9 
 
2.4.4 – Cytokines Polymorphisms 
Polymorphisms in cytokine genes that are associated with an increased immune response are 
also reported by Young in 2006 to be more prevalent in AA patients. In the same article, the 
authors also points out specific examples, like a nucleotide polymorphism in the TNF-α 
promoter at –308 and also homozygosity for a variable number of dinucleotide repeats in the 
gene encoding INF-γ.1  
 
2.4.5 – Telomeres  
This genetic determinant is one of the most recent data presented by literature, with several 
publications nowadays covering this subject.
 9,16,17
 
Young (2006) presents some concepts: telomere loss is compensated by telomerase, a 
telomere repair complex.
1
 The complex consists of the TERT enzyme, a reverse transcriptase, 
and its RNA template, TERC. Telomerophaties was firstly linked to Dyskeratosis Congenita 
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(DC), a CAA syndrome where the unifying feature of patients with DC is the presence of very 
short telomeres
27
 (see section 5.1).  However, Young (2006) pointed some relevant findings 
like the fact that family members who share mutations in TERT or TERC, and short telomeres 
also have hypocellular marrows, reduced CD34+ cell counts and poor hematopoietic colony 
formation. The author also states that all this findings can coexist with normal or near normal 
blood counts.
1 
These data allowed the author to infer that these mutations, and telomere 
length, confer a quantitatively reduced hematopoietic stem cell compartment that could be 
qualitatively inadequate to sustain immune mediated damage.
1
 
Young (2013) widely explored the role of telomeres and telomeropathies and their possible 
role on BM failure.
9
 On the same article the role of TERT or TERC mutations are mentioned 
as being risk factors and not precise genetic determinants of BM failure.
9
  
Dolberg & Levy (2014) presented a rate of 10 to 20% of patients with AAA as having short 
telomeres. These patients are also associated with a lower survival rate and higher  relapse 
rates after treatment (see section 6.3- Definitive Treatment) than those with longer 
telomeres.
13 
 
As mentioned, information about detailed or concrete mechanisms are lacking: what induces 
the breakdown of immune tolerance to antigens on hematopoietic cells is still unclear on 
current literature. 
Nakao et al (2005) suggested that the primary immune response may be directed not to 
antigens restricted to hematopoietic stem cells but rather to antigens expressed by immature 
hematopoietic cells in the BM. The authors explained that immune responses would then lead 
to the production of inflammatory cytokines capable of inhibiting the growth of hematopoietic 
stem cells. They also describe a bystander effect of these cytokines that would be responsible 
for the abrupt loss of hematopoietic cells in the BM.
12
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Young (2006) considers that the molecular basis of the aberrant immune response could be 
represented as a set of susceptibility factors as the ones mentioned above: cytokine gene 
polymorphisms, abnormalities in the regulatory pathways of INF- γ, and the possible role of 
HLA-DR2 for antigen recognition. A set of some these would then lead to marrow failure, 
and the recovery of this stem cell depletion could also be limited for others genetic risk 
factors like telomerase deficiency or short telomeres.
1
  
A recent article by Bueno et al published on March of 2014 should be noted – it actually 
clarifies a question presented by Bacigalup, in 2007 – “Is acquired AA a disease of  the seed 
(HSC) or soil (microenvironment, being this, the stromal cells)?”.6  
Bueno et al (2014) described that BM mesenchymal stem cells (BM-MSC) have 
immunomodulatory and anti-inflammatory properties, being an essential component of the 
BM hematopoietic microenvironment. They are related to regulation of hematopoiesis 
homeostasis through the production and secretion of cytokines and extracellular matrix 
molecules. The results presented in this report states that BM-MSC from AA patients have the 
same phenotype and differentiation potential as controls from normal BM – the authors 
therefore conclude that BM- MSC from AA patients do not have impaired functional and 
immunological properties, being able to support hematopoiesis. They also indicate that 
considering this, BM-MSC do not contribute to the pathogenesis of the disease.
7 
The authors 
also pointed that the study and the BM samples were collected from elderly patients 
diagnosed as N-SAA and SAA (see section 6.1 for Classification of Severity) and for that 
reason larger studies are necessary to unravel whether age at the diagnosis and the disease 
severity can affect the homeostasis and function of the BM microenvironment. However, 
these results strongly support that the HSC are the main target of the immune mechanism. 
In conclusion, most of literature supports the role of the immune system and the dysfunction 
in the immune response as the responsible for the HSC cells as the main target[u3]. Nissen & 
    
20 
 
Stern published in 2009 a new hypothesis that should be mentioned for the possible new 
insight about the role of immune system in some cases of AA.
18 
In the mentioned article, the 
authors states that autoimmunity can inhibit growth of solid tumors, and that this anti-tumor 
activity can also be applied to hematologic diseases – raising then the question that malignant 
altered cells may be preexisting. Autoimmunity against hematopoietic stem cells may reflect 
an attempt to eradicate these malignant cells, instead of considering the primary event the 
dysfunction of regulatory T-cells (leading to the sequential BM failure). The same hypothesis 
is supported by reference to some recent observations – and can also elucidate about some 
questions concerning the eventual outcomes of IST therapy, like clonal evolution (see section 
6.3 – Definitive Treatment). 
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3- Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria 
Paroxysmal Nocturnal Hemoglobinuria (PNH) is described as an acquired hemolytic anemia 
with a classic triad of hemolysis, thrombosis and marrow failure. It is also known to be caused 
by a clonal expansion of a hematopoietic progenitor cell that has acquired a mutation in the 
X-linked phosphatidylinositol glycan class A (PIG-A) gene.
19 
The relationship between AA and PNH had been widely documented. Historically AA was 
described as a condition that evolve to PNH.
20  
However, recent publications allowed a 
different perspective - it is now proved that about 40-50% of AA patients have a PNH clone 
detected at the time of diagnosis.
21
 
 
3.1- Genetic features of PNH 
The clonal expansion of a PNH clone leads to a cluster of cells which are deficient in all 
proteins linked to the membrane by a glycosylphosphatidylinositol molecule (GPI-anchored 
proteins).
19
 This is reported as being due to somatic mutations in the X-linked PIG-A gene.
19
 
Another particular note is that the localization on the X chromosome in addition to the 
lionization in female somatic cells, leads to the conclusion that only one mutation is required 
in either males or females to abolish the expression of GPI-linked proteins.
19 
PNH is a hematologic disease and to date PIG-A gene mutations have only been described in 
hematopoietic cells. In PNH patients GPI-anchored proteins are lacking from variable 
proportions in the different hematopoietic cells, and are also consistent with the activity of an 
aberrant hematopoietic stem cell clone.
20 
 
 
3.2 – Pathophysiology 
Pathophysiology of PHN is widely studied – Bessler & Hiken directly address and clarifies 
this subject on a publication in 2008.
19 
The authors described the two central pathophysiologic 
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components as being BM failure and the occurrence of blood cells that are deficient in GPI-
anchored proteins. BM failure is reported as being a finding present in all patients with PNH, 
(even with normal peripheral blood counts and a hypercellular BM). The degree of BM 
failure however is described as variable.
 
The authors also explain one of the most characteristic features of PHN – the complement 
activation. This phenomenon is reported to occur due to the lack of GPI-anchored proteins in 
PNH blood cells. In normal conditions complement activation should be regulated by specific 
proteins, present on the surface of normal human cells. These proteins are identified as two 
GPI-linked inhibitors of complement activation, CD55 (decay accelerating factor, DAF) and 
CD59 (membrane inhibitor of reactive lysis, MIRL) as well as one membrane cofactor protein 
(CD46, located at the plasma membrane via a transmembrane domain). Erythrocytes lack 
CD46 and express only CD55 and CD59, in opposition to platelets or white blood cells which 
express also CD46. This last fact is described as the reason of the massive intravascular lysis, 
and the classic hemoglobinuria which named the disease.
19
 
 
3.3- Clinical Features  
Clinical features are also described by Bessler & Hiken (2008): PHN is reported here as a rare 
acquired chronic disorder, with no inherited form described.
19
 Affects both gender equally 
and no differences in incidence are reported concerning variables like socioeconomic status or 
geographic worldwide distribution. The clinical manifestations described are those of a 
hemolytic anemia, acquired thrombophilia, and BM failure. The degree to which each 
contributes to the clinical presentation is reported to be variable between patients and during 
the course of the disease.
 19 
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It is also reported that the diagnosis is mostly done in young adults, but there’s data reporting 
that it can be done at any age. Currently, flow cytometric analysis is the preferred laboratory 
test for diagnosis purposes.
19
  
Treatment options are clear in all recent publications – one increased understanding of 
pathophysiology of this disease in the last years allowed the introduction of complement 
inhibitors (Eculizumab) which directly improved management and treatment prognosis.
19,20
 
 
3.4- Idiopathic Aplastic Anemia and PNH  
Young et al, in a 2002 publication, reported that flow cytometry testing indicated that marrow 
failure and PNH clonal expansion frequently coexisted, this being apparent in 40-50% of 
patients at the time of diagnosis of AA.
20
 These findings justifies the interest of scientific 
community in the clarification of a possible relationship between both entities, leading to the 
several publications regarding this subject. 
The mechanism responsible for the expansion of PNH cells in AA - even if several 
hypotheses were already proposed and tested - remains unknown. In 2002, on the cited report, 
Young et al had already included a review of some of them
20
: one hypothesis relay on the fact 
that PIG-A deficiency could confer on mutant cells an intrinsic growth or survival advantage 
– however, the authors states that clinical observations showed that PNH as a disease doesn’t 
reveal an invasive character. Most patients are even reported to maintain a stable proportion 
of PNH cells over the years. To support this, the authors also cited results from studies with 
chimeric knock-out mice (with PIG-A mutate cells), that, after being cross-pated with analysis 
of the transcriptome of normal and PNH cells, showed that PIG-A mutation wasn’t associated 
with major changes in the cell's program for growth, differentiation, or death. For last, small 
PNH clones can also be identified in normal individuals, and the authors refered that this 
finding doesn’t have any clinical significance.  
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Another hypothesis was formed considering precisely the frequent association of PNH with 
AA - this circumstance suggested that the hypocellular marrow might be an extrinsic factor to 
promote clonal expansion of PHN cells. However, even that PNH clones are present in a very 
large proportion of  IAA patients, PNH does not occur after other conditions that could lead to 
a hypocellular BM like chemotherapy, radiation-induced aplasia or following stem cell 
transplant. The authors conclude that PNH as a clinical entity does appear to correlate mainly 
with immunologically mediated marrow failure.
  
Another relevant fact analyzed by the authors is that IAA and PHN/AA shows the same 
pathologic mechanisms: using fine analysis of T cell receptors it is reported to be possible to 
confirm that the immune response is antigen driven in PNH/AA, exactly like IAA. Young et 
al, cited a study of patients with PNH/AA, where was found not only a limited utilization of 
the Vβ chain of the T cell receptor, but that among different patients the dominant CD4 T cell 
clones used had identical CDR3 region for antigen binding. It is also reported that this CDR3 
region specifically inhibit autologous hematopoiesis.
20
  
In other study by Chen et al, also cited in the 2002 article by Young et al,  it was reported a 
deficiency among the normal cells rather than an advantage for the PIG-A mutant cells. 
Methodology included the culture of CD34+ cells, which were separated based on the 
presence or absence of CD59, and cultivated in the presence of growth factors. The authors 
described that the cells of PNH phenotype behaved normally, without any sign of impaired 
production, while CD34+ cells of normal phenotype showed little growth.
20
 These results are 
similar with those found in IAA as already mentioned on section 2.2 - where minimal 
numbers of colonies derived from committed progenitors revealed a transcriptome in which 
genes involved in apoptosis, cell death and immune regulation were upregulated
1
. 
Analyzing this results a conclusion is already lined - the difference between GPI deficient 
cells and normal CD34+ cells can indeed be explained by an immunologic mechanism. The 
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authors reported that exactly like CD34+ cells for AA, also normal CD34+ from PNH had a 
raised expression of FAS and concomitant sensitivity to FAS-ligand mediated apoptosis that 
wasn’t seen in the GPI-anchor protein deficient cells. Young et al (2002) also have  
reproduced these results: when comparing CD34+ cells of the PNH phenotype with normal 
BM cells from the same patient, these last showed lower cloning efficiency, increased FAS 
receptor expression, and also increased apoptosis. 
These results support the most acceptable possible mechanism for clonal expansion in PNH, 
that is also presented by Young et al, in 2002, and still remains as the most likely and still 
referred in newest publications
19,21,22
 - PNH cells may indeed have a proliferative advantage 
over non-PNH cells, not by intrinsic growth or survival advantage, but by an immune 
mechanism of selection. Some GPI-anchored proteins are ligands for T cell receptors, 
including CD58 and CD59, or serve immune functions, as do CDI4 and the Fc III receptor
20
. 
The absence of these molecules or the ligands for T cells receptors could then result in a 
failure of PNH cells to be recognized by the immune system – creating a possible path to 
escape from immune surveillance. Young et al, also refers that most experiments to directly 
test this possibility had been negative – however these authors and others had mentioned, the 
effect described could be so specific that only manifest under special in vivo circumstances. 
Until now, there aren’t any publications to clarify this subject. 
For last, in the referred 2002 report, the hypothesis that the PNH cell might have a more 
primary role in the development of BM failure is also stated. Several mechanisms that could 
lead to this pathology are also mentioned: first, GPI-anchored proteins might serve as antigens 
by themselves. The authors also explain that this could happen by two mechanisms: due to 
molecular mimicry with exogenous peptides, or being directly involved in the process of 
antigenic spread. Secondly, the PNH clone itself might induce autoimmunity – and this could 
happen considering the normal physiology of protein trafficking. It is clarified that due to 
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absence of GPI anchors, GPI-anchorless proteins in the PIG-A- cell be processed by the 
proteasome and their peptides displayed via class I HLA. In the normal circumstances, the 
membrane-bound protein degradation should occur in lysosomes, leading to presentation of 
peptides in the context of class II HLA instead of I HLA.
20 
 
3.5 – AA/PNH syndrome – a predictive indicator?  
As seen, about 40-50% of AA patients have a PNH clone detected at the time of diagnosis
21
, 
and during management of PNH, AA/PNH syndrome is already referred as one clinical 
subgroup
19 
in some publications. 
There is no significant difference reported between the different classifications of severity of 
AA (see section 6.1) and the detection of a PHN expanded clone. Considering this, a major 
question arises: what means the presence of this expanded clone and what consequences 
could it bring for patients? 
The literature contradicts what could be the first negative conclusion resulting from a 
introduction of a second diagnosis of another rare disease, that was reported with such 
potentially serious consequences - in the past, therapy of PNH was often restricted to the 
treatment and prevention of complications (e.g. red blood cell transfusions for the treatment 
of anemia or immunosuppression for the treatment of BM failure). PNH was also associated 
with increased propensity for the development of life-threatening venous thrombosis, being 
also reported that patients with a large PNH clone were at a higher risk of developing 
thrombosis than patients with a small PNH clone. However, introduction of complement 
inhibitors for the treatment of PNH was a major advance in the management and prevention 
of these complications
19
- eculizumab, a monoclonal antibody directed against the complement 
protein C5, is reported as effective in blocking intravascular hemolysis and reducing the 
incidence of thromboembolic events in patients with PNH.
21 
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IIt is reported that having a PNH clone at time of AA diagnosis is associated with low 
morbidity and mortality (considering only the implications that PHN as a clinical entity could 
bring), and specific measures to clinical management of PNH are seldom required
21 – this 
conclusion is broadly stated in several reports, and a retrospective analysis by Scheinberg et 
al (2010) is particularly representative of this. In the quoted publication, authors presented the 
results achieved by quantification of PNH clones by flow cytometry of 207 patients classified 
as severe aplastic anemia (SAA) (see section 6.1) who had received immunosuppressive 
therapy (IST) with a horse anti-thymocyte globulin (h-ATG) based-regimen (see section 6.3), 
concerning the period from 2000 to 2008[u4][u5]. A total of 83 patients (40%) had a PNH 
detected prior to treatment and the response rate for all patients was 62% - there was no 
difference in response rate between patients with or without a pre-treatment clone. Therefore, 
the presence of a PNH clone does not 
directly interferes with IST response in 
AA. A summary of the results obtained  
is presented in Table 2. 
Some results, due to their significance 
should be underline – first, the concept 
that PNH was a condition evolving from 
AA is once more widely contradict -  
the development of a PNH clone in 
patients who do not have a pre-existent 
clone prior to IST is uncommon (21%). 
Secondly, in those with a pre-existing 
clone, a decrease in clone size is likely 
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to occur in the years following IST - only about 25% of those with a pre-treatment clone had 
an expansion.  
Clinically, hemolysis was reported as being mild or subclinical in the majority of patients – 
and symptoms only occurred when the clone size was large (>50%). Authors also states that 
only less than 5% of patients required specific interventions for PNH. 
This study underlines a management strategy widely adopted worldwide - in clinical practice 
patients with SAA are treated with IST regardless of the presence of a PNH clone. The 
detection of this PHN clone is even considered as a mandatory step in the management of a 
potential IAA case. This strategy will be explored further in this document, on section 6.  
Scheinberg et al (2010) also explained the reason for this strategy - resumption of 
hematopoiesis must be seen as the primary goal, once that specific therapy for PHN like 
eculizumab doesn’t have a role in improving marrow function.  
Concerning AA, even that some others studies reported that the presence of a clone has been 
reported to be predictive of response to IST, in this study that was not observed. 
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4- Clinical Features  of Idiopathic Aplastic Anemia 
Clinical features of IAA are reported to be directly related with the definition of the disease: a 
clinical entity that includes the presence of pancytopenia (with at least two of the following 
required: hemoglobin (Hb) <10 g/dL; platelet count <100 ×10
9
/L; and neutrophil count <1.5 
×10
9
/L) alongside a hypocellular BM (in the absence of an abnormal infiltrate and with no 
detectable increase in reticulin).
25 
Pancytopenia is widely reported as the first indicator to be unrevealed: it may cause the 
symptomatology that leads the patient to seek medical attention, or it can be discovered 
occasionally in asymptomatic patients in the set of procedures like preoperative evaluation, 
blood donation or any other analytical investigation.  
When symptomatic, patients can present the symptoms related to anemia or 
thrombocytopenia. Neutropenia, even if severe, it is reported as being asymptomatic and 
infection at presentation as infrequent. 
24 
 
Anemia, can lead to classic symptoms like fatigue, tachycardia, headache, dizziness, leg 
cramps or insomnia. Physical exam of these patients can reveal findings like a forceful 
heartbeat, strong peripheral pulses and/or a systolic "flow" murmur. The skin and mucous 
membranes may be pale when Hb is lesser than 8 to 10 g/dL.
8
 
Thrombocytopenia, can lead to findings and symptoms like skin or mucosal hemorrhage, 
epistaxis, or even visual disturbance (which results from retinal hemorrhage).
8
 
Physical findings like lymphadenopathy or hepatosplenomegaly, which could be related with 
anemia or thrombocytopenia, are not present in AA, and strongly suggest another diagnosis 
(see section 5). 
Literature is objective in this topic – there are no specific symptoms or signs, and no 
pathognomonic finding is described or reported.  
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5- Differential Diagnosis  
IAA, despite the precise definition criteria, is considered a diagnosis of exclusion – besides 
the Congenital AA, as there are also a largely collection of other hematologic conditions 
documented that can lead to pancytopenia or hypocellular BM.  
Diagnosis is strongly recommend to be founded on a step-by-step approach (see fig.1, section 
5.3), comprising a narrow clinical history, a detailed physical examination alongside one 
thorough investigation. In the end, all the findings must allow to confirm the diagnosis, 
exclude other possible causes of pancytopenia with a hypocellular BM, Congenital AA or 
Secondary AA, assess the severity of the disease and define the best treatment option. This 
judicious approach is indispensable and substantiated in several publications - treatment and 
management options may vary with the different causes of pancytopenia and BM failure. 
There’s also a clear relationship documented between time taken from first medical contact 
and the beginning of treatment in a confirmed IAA case, so all the efforts must be to making a 
correct diagnosis in the shortest time possible. 
The next two sections (5.1 and 5.2) comprise a summary of some clinical entities that 
literature states as some of the pathologies that should always be present in clinical logic as 
possible differential diagnosis. 
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5.1 – Congenital Aplastic Anemia 
As mentioned in the sections above, there are several forms of Congenital AA and current 
literature make aware that some patients may not present the classic signs and findings 
usually described. These syndromes may become true diagnosis challenges, leading to a 
generalized recommendation from the majority of authors: every physician who deal with 
potential IAA cases should be familiarized with some characteristics which may allow a 
correct differential diagnosis. 
There’s also a consensus on the fact that labeling of IAA rather than one of the CAA 
syndromes is more than a semantic division. A correct classification is widely reported as 
having implications for treatment options, and also allowing the possibility of genetic 
counseling for other family members.  
There are plenty publications regarding CAA and a report by Weinzier & Arber (2013)
25
 is 
particular exhaustive considering these syndromes and others causes of pancytopenias.  
Considering that one extensive description of each one of CAA syndromes isn’t the aim of 
this document, Table 3 presents a synthesis of some features concerning few characteristics of 
the syndromes most representatives in the clinical setting. 
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5.2 – Differential Diagnosis of others Pancytopenias 
Besides Congenital AA, there is a substantial number of others diseases that can lead to 
pancytopenia. A summary is presented in Table 4.   
A special attention should be given to those entities that besides pancytopenia also reveal a 
hypocellular BM, leading to an increased diagnosis dilemma. 
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5.3 – Investigation 
As mentioned, several scenarios are reported as potential reasons to lead to the first step of 
investigation – patient can seek medical attention, due to pancytopenia related symptoms, or 
blood count abnormalities be revealed during any other clinical routine/practice. Regardless 
of the reason, it is widely recommend that a proved and documented pancytopenia should 
always be clarified, and most of all, correlated with the condition underlying it. 
On section 5.1 and 5.2 it was presented certain entities that are documented as the ones that 
the physician should be acquainted with when managing a potential IAA patient. On the other 
hand, it is also reported that any thorough investigation must be compatible with a period of 
time that will not compromise the beginning of treatment of the pathology subjacent (IAA or 
any other). A simplified and 
outlined protocol may reduce the 
delay between first medical contact 
and decision, allowing a standard 
approach in every potential patient – 
it is now presented a proposal, that 
according with recent literature, 
incorporates all the exams that are 
vital, and, therefore, must always 
guide medical practice in these 
cases. It is widely reported that in 
most cases a test or exam can’t 
dictate an exact diagnosis, and none 
permit to allege IAA.  
As conclusion, it’s then possible to 
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state that a correct diagnosis it’s only possible by an interconnection between clinical features, 
genetic and biological results. 
Figure 1 represents the step by step proposal that may support this strategy and Table 5 the 
investigations that the majority of literature states as the ones required for the diagnosis of 
AA.  
 
 
Figure. 1- Step-by-step approach and investigations that should be underlying it.  
Step 3 and 4 refers to a confirmed IAA case. 
 
AA- Aplastic Anemia, BM- Bone marrow, CAA- Congenital Aplastic Anemia, FBC- Full blood count, PHN- Paroxysmal 
Nocturnal Hemoglobinuria, TCR- T cell receptor, T-LGL- Large granular lymphocyte leukemia 
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5.3.1 – Clinical history  
It is consensual that a detailed interview followed by a narrow physical exam is fundamental 
regardless if the patient seeks medical care for symptomatology or in the setting of occasional 
analytic findings. It is recommend an effort to reveal a possible link between personal 
background and exposures to chemicals, pesticides or drugs. Concerning drug history, it is 
highly remarked that a special awareness should be lead to the ones that could had been 
consumed during the period that comprises six months before and one month prior
29
 to date – 
ideally, this step could reveal some possible etiologies for Secondary Aplastic Anemia (see 
Table 1). Even that no test allows ascertainment of causal relationships between exposure and 
subsequent BM failure
30
, it is highly recommended that any possible related chemical 
exposure should be removed, or any putative drug discontinued or given again to the patient.
29
  
Medical history and correlation with physical exam could route to a possible Congenital AA 
(see section 5.1). Age of the patient is also a major clue, and CAA is indeed related to earlier 
ages. However, all the later presentations reported should alert the clinic – and all this 
findings should be correctly studied and registered/excluded. Family history is also relevant – 
some of these disorders are correlated with a considerable phenotypic heterogeneity
28
, like, 
for example, DC. The substantive limitations of the examination in firmly excluding 
alternative diagnoses previously felt to have pathognomonic findings
30
 doesn’t allow to 
prescind the specific diagnostic tests that are recommended to incorporate the next steps of 
investigation. 
Others pathologic backgrounds should also be excluded – a preceding history of jaundice 
(usually 2-3months before)
29
 for a possible post-hepatitic AA, as well as previous viral 
infections or acquainted immune diseases.  
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Physical findings like lymphadenopathy or hepatosplenomegaly (in the absence of current 
infection) are not correlated with IAA
29
 – and this observation should lead the practitioner for 
a different diagnosis. 
In conclusion, this topic directly relates to Aplastic Anemia and the subdivision in Congenital 
or Acquired (Secondary or Idiopathic). 
 
5.3.2 – Investigations required 
5.3.2.1 - Confirmation of AA 
Full Blood Count, Reticulocyte Count, Blood Film and % Hbf 
For an IAA diagnosis, it is consensual that full blood count (FBC) should show pancytopenia, 
with a preserved lymphocyte count. In very early stages it is reported that the finding of 
isolated cytopenias may occur.
29
 Reticulocyte count should show reticulocytopenia – being 
this a sign for BM failure. Blood film analyses should focus on what not to expect in IAA: 
dysplastic neutrophils, abnormal platelets, blasts or any other abnormal cells should lead the 
investigation to other different entity besides IAA. Common findings are documented to 
include anisopoikilocytosis and possible toxic granulations in neutrophils.
29
 HbF (fetal 
hemoglobin) can be related to some CAA syndromes
26 
(see section 5.1), and it is 
recommended that it measurement should be done before any blood transfusion. 
 
Bone Marrow Examination 
BM examination should include both aspirate and threphine biopsy. Descriptions about 
findings in aspirate include hypocellular fragments with prominent fat cells and variable 
amounts of residual hematopoietic cells. It is also clear that erythropoiesis, megakaryocytes 
and granulocytic cells must be reduced or absent. Lymphocytes, macrophages, plasma cells 
and mast cells however, are described as prominent. Dysplastic cells aren’t reported as a 
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feature in IAA, but dyserythropoiesis is considered common and can also be marked.
29 
Another finding related to the early stages of the disease, is a possible prominent 
haemophagocytosis by macrophages, and also background eosinophilic (which may represent 
interstitial edema).  A BM trephine biopsy, of at least 2 cm, is indicated as necessary to allow 
assessment of the overall cellularity, the morphology of residual hematopoietic cells and also 
to exclusion of an abnormal infiltrate.
29
 Findings including an increase of reticulin or any 
other abnormal cells are not expected results at IAA and should be directly linked with others 
possible diagnosis. Increased blasts are a finding that literature recommends that when present 
should immediately lead to two other possible etiologies:  hypocellular MDS or evolution to 
leukemia.  
 
5.3.2.2 - Exclusion of others etiologies: 
Determination of vitamin B12 and folate levels 
In order to exclude megaloblastic anemia it is highly recommended that any documented 
deficiency of B12 or folate should be corrected before a possible final diagnosis of IAA. 
 
Liver function tests  
Liver function tests should be performed to detect previous hepatitis.  
 
Viral serology studies 
The recommended regular viral studies include hepatitis A antibody, hepatitis B surface 
antigen, hepatitis C antibody and Epstein–Barr virus (EBV).  Cytomegalovirus (CMV) and 
other viral serology should be included if BMT (see section 6 - Treatment) is being 
considered.  It is also mandatory the exclusion of HIV. 
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Autoantibody screen 
Anti-nuclear antibody and Anti-DNA antibody are recommended to exclude a systemic lupus 
erythematosus. 
 
Congenital AA syndromes 
FA should be screened by chromosomal breakage test with diepoxybutane (DEB) or 
mitomycin C (MMC). This test is recommended by all literature as screening for FA as 
regular basis, and mostly to those who are BMT candidates (see section 6). Some authors set 
an upper age limit for screening, but the reported cases occurring in the fourth or fifth decade 
makes this topic uncertain. Marsh et al (2009) guidelines
29
 doesn’t include an age limit, and 
most recent reports set a limit between 40 to 50 years old. 
Others syndromes screening remains controversial. Genetic testing has theoretically an 
undeniable interest and possible use for screening of CAA - however, the generalizable 
message is that these tests provide incomplete information, considering all of the inherited 
genetic variants of CAA syndromes that are still unknown .
30
  
Therefore, the following tests, even that are potentially associated with some CAA, are not 
recommended as routine clinical service: 
 Identification of mutations in DKC-1, TERC or TERT genes, determination of 
telomere length alongside information with nomograms of telomere length by age and 
by cell of origin, if there are a suspicious of Dyskeratosis congenita.
30 
 SDBS gene analysis in cases of Scwachmann-Diamond Syndrome31. 
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5.3.2.3- Other Investigations 
Radiological Investigations 
A chest X-ray is recommended for all patients at presentation as a way of exclusion for any 
infection and to comparison with subsequent films. Abdominal ultrasound should be 
performed to exclude lymphadenopathy or splenomegaly. Abnormal or anatomically 
displaced kidneys can also be associated with a possible FA case. 
 
PNH clone 
PNH exclusion should be excluded and the presence of a PNH clone should be documented
32
 
– it should be done using flow cytometry and in the neutrophil and monocyte lineages. 
FLAER is currently the most sensitive technique.
30
  
 
Cytogenic Investigations 
It is reported that approximately 10% of patients with apparent aplastic anemia by all other 
criteria may have clonal chromosomal abnormalities.
30 
The presence of abnormal cytogenetics 
at presentation in children, especially monosomy 7, can be an indicator to the likelihood of 
MDS but abnormal cytogenetic clones may also arise during the course of the disease – this 
situation is explored at section 6.3. 
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6-Treatment Options 
6.1- Assessment of severity  
AA is classified according to the severity of the disease – and this classification is commonly 
used to underline the treatment strategy. 
Camitta criteria, published in 1975 by Camitta et al, remains the most widely criteria used, 
and a sub-classification proposed by Bacigalupo et al in 1988 is also frequently  associated - 
both can be seen on table 6. 
 
 
Management of a newly diagnosis IAA patients usually assumes some fundamentals, which 
had arised from several clinical observations. Therefore, SAA and VSAA patients requires 
treatment, both supportive and definitive – this is a clear point, and no controversy is 
underlying it. N-SAA, represents a different case, without consensus on literature. The 
majority of publications and clinical practices suggest that in these cases, observation can be 
appropriate, especially if patients are blood transfusions independents. Clinical experience 
often shows that most of these patients may have stable blood counts for years.
24
 The 
evolution and prognosis however, are not certain - some patients are reported to evolve to 
more severe pancytopenia, meeting the criteria for SAA or becoming transfusion-dependent, 
and in this cases, it is recommend the same management as SAA primary cases.
24,13
  This 
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approach is the most commonly reported, and therefore, blood counts of these patients should 
be routinely monitored.
29 However some recent reports shows that a “watch and wait 
practice” could be associated with low response rate and poor long-term outcome after IST 
(see section 6.2 - definitive treatment) and, therefore, further controlled studies are warranted 
to determine the optimal treatment strategy in these cases.
33
 
Other controversial subject is the validity of Camitta Criteria as prognostic significance in the 
present clinical era – many throwbacks are stated against these criteria, supporting a possible 
modification. The first topic of discussion is due to the conclusion that routine and more 
accurate automated reticulocyte counting (available nowadays) will lead to an over-estimation 
of the level of reticulocyte count used in the cited criteria.
29
 
Secondly, other variables had been widely reported as having a direct connection with 
positive outcomes, like age at diagnosis, telomere length and interval of time between 
diagnosis and treatment. That leads to infer that considering only blood counts should not be 
taken as the single factor that could affect overall survival (OS). Therefore, the criteria should 
ideally be correlated with all the cited variables. 
At last, there is also a recent report
34
 that focus the fact that no studies have reviewed or 
validated Camitta criteria, even after these becoming the most widely accepted standard for 
the diagnosis of AA. The publication also cites another study where it is reported that 
neutrophil count is indeed one factor that is directly linked with overall survival, and therefore 
should not be considered an optional criteria.
34
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6.2 - Supportive Care 
Before any definitive therapies, it is widely reported and recommended to be assed if the 
patient requests any supportive measures. Supportive measures alone are not considered as 
definitive therapies, and it is recommended that definitive options should always be 
considered in SAA cases. Exceptional cases are described as to be the ones concerning 
elderly, feeble, or patients with serious comorbidities that may not benefit from the 
approaches described in section 6.3. As some publications states, those patients may remain 
stable and maintain quality of life with regular red blood cell transfusions.
24 
The majority of publications and guidelines available reported that the initial immediate 
management in the majority of patients should consist of blood transfusions, platelet 
concentrates and treatment or prevention of infection.  Each clinical institution may define the 
protocol to be followed, but, most clinical data reveals some points that should be taken in 
consideration: 
 
Transfusions 
 Blood products should be irradiated to prevent transfusion associated graft-versus-host 
disease (GVHD) and filtered to reduce the incidence of viral infections and prevent 
alloimmunization;
35
  
 Transfusions from family members should be avoided to decrease sensitization to 
potential BM donors;
35
 
 The initial goal of transfusion therapy for anemia should be to correct or avoid 
cardiopulmonary complications, and therefore, patients should only be transfused with 
packed red blood cells when symptomatic
35
 - overuse of blood products should be 
avoided, but so also should inadequate transfusions;
24
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 It is recommended to give prophylactic platelet transfusions when platelets are less 
than 10 x 10⁹/l (or less than 20 x 10⁹/l in presence of fever);24,29,32 
 If the patient is a potential BMT candidate (see section 6.3), CMV negative products 
should be used until CMV status is known;
29,32
   
 Granulocyte transfusions remain controversial35, but irradiated granulocyte 
transfusions may be used in life-threatening infections
32
; 
 Iron chelation therapy should be considered when the serum ferritin is >1000 
ng/mL;
29,32
 
 
Growth factors 
Measurement of endogenous serum levels of hematopoietic growth factors (HGF) in patients 
are reported as being markedly elevated
35
, predicting that the use of these is of limited value 
in AA. Therefore, current publications state the following recommendations:  
 There are no effective or safe hematopoietic growth factors to support red cell and[u6] 
platelet counts in AA patients;
29
  
 There may be a limited role for granulocyte colony stimulating factor (G-CSF) 
administration in an attempt to stimulate a neutrophil response in the presence of 
severe infection
35
 but recent guidelines recommends that this should be given as a 
short course and it should be discontinued after one week if there is no improvement 
in the neutrophil count
29,32
; 
 
Infection 
Fungal and bacterial infections are a major cause of death in patients with SAA
35
, so it is 
highly recommended that: 
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 Prophylactic antibiotics and antifungal drugs should be given to patients with an 
absolute neutrophil count <0.2 x 10⁹/l according to institutional guidelines;32 
 Aspergillus species are responsible for high incidence of infections in AA, but  
Pneumocystis jiroveci infections are rare among patients with SAA, considering that T 
cells are not defective
35
. There is no indication for routine prophylactic measures 
against this last agent, or anti-viral prophylaxis in untreated patients with aplastic 
anemia;
29
 
 Patients who are severely neutropenic (ANC <0.2 x 10⁹/l) should ideally be nursed in 
protective isolation;
32
 
 Foods that may be contaminated with bacteria or fungal pathogens must be avoided;29 
Patients at intermediate risk of infection (neutrophil count 0,2-0,5 x 10⁹/l) has less clear 
recommendations – and the decision is best determined on an individual basis according to 
the frequency and severity of previous infections.
29 
 
Psychological support  
Considering the chronic nature and slow response to any of the options of definitive 
treatment, patient and family should be closely followed by a multidisciplinary team – besides 
physicians and other clinical staff, it is highly recommended that it must be also composed by 
psychologists and others professionals. Patients and relatives should also be offered 
information about relevant support groups available.  
 
Supportive care is therefore reported as being fundamental at AA management – even when 
patients are already through definitive treatment modalities (see section 6.2 and 6.3), due to 
the usual delayed response of blood counts. 
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6.3 - Definitive Treatment  
The aim of definitive treatment is pretty clear: the restoration of hematopoiesis. They are 
currently two options proven to be effective on this goal: hematopoietic stem cell 
transplantation (HSCT) or immunosuppressive therapy (IST). 
Advances in both techniques are described to be the main reason to the major improvement 
on survival in SAA when compared with oldest reports. It had led to a very different 
optimistic vision before a pathologic entity that represented in the past survival rates of 10-
20%. Survival rates of SAA are now bruited to be around 80-90%.
36
 
Overall long-term survival is reported to be comparable with both treatment modalities – 
therefore, the decision between both should include the consideration of factors like age, 
presence of a histocompatible donor and others comorbidities.  
It is also widely recommended that any patient should be clinically stabilized before being 
referred to any of the treatment options, implying the inexistence of any proven infection or 
uncontrolled bleeding. IST given in these cases has resulted in possible detrimental outcomes 
and even life threatening complications. The presence of infection is also considered an 
adverse factor for outcome after HSCT
29
. Exceptional cases are described, in which it may 
exist the necessity to proceed with HSCT even in the presence of active infection, considering 
that transplant offers the best chance of early neutrophil recovery. Therefore, it is recommend 
a special caution in those cases where a delay in definitive treatment may lead to a lethal 
progression of a possible infection.
29
 
It is usual that different institutions adopt different protocols for concrete management – 
however, there is a worldwide accepted algorithm treatment that, being structured based on 
several reports, is also recommended by the most recent publications. This algorithm is 
presented on figure 2. 
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Figure 2 - Treatment algorithm for patients with a recent diagnosis of SAA.  
Even that sibling HSCT is the first option at younger patients, at any age the presence of significant comorbidities should 
favor IST as the initial treatment.  
 
AA-Aplastic Anemia, HSCT - Hematopoietic Stem Cell Transplantation, IST- Immunosuppressive therapy,  SAA- Severe 
Aplastic Anemia  
 
There’s a clear recommendation from almost the majority of publications: definitive treatment 
should not be delayed much beyond the necessary time to clinically stabilize the patient, 
confirm the diagnosis, assess severity, typing of a potential HLA sibling donor and a 
management planed discussed.
29
 Early spontaneous recovery are reported to occur 
infrequently, and therefore, watchful waiting can be harmful and completely inappropriate in 
SAA or VSAA patients.
24
  
Corticosteroids are of unproven benefit and inferior to conventional immunosuppression 
regimens
24
, being ineffective as a mean to treat AA – they are also more toxic and can lead to 
bacterial and fungal colonization or precipitate serious gastrointestinal haemorrhage
29
 in the 
presence of severe thrombocytopenia.   
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6.3.1- Hematopoietic Stem Cell Transplantation (HSCT) 
HSCT from a HLA identical sibling donor is considered the treatment of choice for a newly 
diagnosed patient if they are under 40 years old (there’s some controversy, but most 
orientations states this as the preferred age limit), who has SAA or VSAA.
29
  
This treatment is described in literature as one potential curative option, representing a 75-
90% chance of long term cure.
29 
The setting of the age limit present in the majority of 
guidelines can be explained by the correlation of increasing age with the risk of graft-versus-
host disease (GVHD).
23
 GVHD can lead to significant morbidity and mortality after 
transplantation, possibly overcoming the potential benefit. Therefore, age of the patient is 
described as one of the factors that directly determine the decision to choose IST over HSCT 
as first choice treatment.  
BM grafts are recommended to be the preferred stem cell source, since the peripheral blood 
stem cells grafts had showed inferior positive results, and also a higher rate of complications 
like GVHD.
23 
It is also highly recommended that all younger patients without a matched sibling donor 
(being the IST the first choice in those cases) to be screened at the time of initiating IST for a 
potential HLA-matched unrelated donor.
37 
The most commons complications of transplantation identified are graft failure, acute and 
chronic GVHD. 
Transplantation protocols may differ, but there is a worldwide consensus about the use of  
cyclophosphamide (Cys) and antithymocyte globulin (ATG) as conditioning and cyclosporine 
(CsA) and methotrexate as GVHD prophylaxis.
37
 
There is also several references to the use of fluradabine (FLU) in addition to Cys plus ATG 
regimens to enabled engraftment in heavily transfused and sometimes alloimmunized 
patients.
35,37 
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There’s also data reporting that with a FLU, Cys and alemtuzumab (ALZ) conditioning 
regimen for SAA, the rates of extensive chronic graft-versus-host disease and graft rejection 
are now less than 5%.
38
 
Availability of an HLA-matched sibling donor is described as being around 30%.
35
 
Unrelated donors and mismatched transplants had been reported to have almost twice the 
transplant-related mortality and risk of GVHD as matched sibling donor transplants – 
however, there are publications reporting a major improvement on the outcomes with 
unrelated donor (UD) HSCT. These same publications directly relate these outcomes with 
more stringent donor selection facilitated by high-resolution molecular typing, less toxic and 
more effective conditioning regimens in addition to higher quality transfusion and 
antimicrobial supportive care.
24
 
Experience from larger cohorts reported in the last couple years from the United States, Japan, 
Korea, and Europe suggests that the outcome with UD HSCT is still not as favorable as that 
of a matched sibling donor
24
 - therefore, BM transplant (BMT) from unrelated or mismatched 
donors is mostly recommended to be seen as an second option reserved for patients who 
failed to respond to one or more courses of IST. 
Younger patients are currently a target of controversy in this matter – even that some authors 
state that UD HSCT is not recommend as first therapy for SAA
24
, a recent report
38
  by 
Samarasinghe et al (2014), doesn’t exclude this option as a first treatment choice, considering 
that compared to IST, transplantation offers a more complete restoration of hematopoiesis, 
lower relapse rates and better protection against secondary cancers (see section 6.3.2). 
The potential drawbacks to this new approach are equally presented by Samarasinghe et al 
(2014).  This report mentioned several concern aspects like the difficulties in finding donors, 
the time from diagnosis to stem cell donation, GVHD risk, donors opting to donate peripheral 
blood stem cells rather than BM and treatment-related mortality. The authors also mention 
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that the long-term survival among children who respond to horse antithymocyte globulin 
(ATG) plus CsA is excellent, approximating 90%, and that an optimal conditioning for UD 
HSCT is not yet defined. 
The delaying time between definitive IST while conducting a search for a nonfamily donor 
may be dangerous
24
, and this is one of the major negative factors. However, the 2014 report 
presents a new perspective, introducing the results of a study by Yoshimi et al: the median 
time from diagnosis to administration of IST was 60 days while it was 134 days in those who 
were submitted to upfront matched UD HSCT.
39
 Even considering that IST can always be 
started earlier than a transplant option, the time to cellular recovery following IST is reported 
as 3-6 months. Cellular recovery following matched UD HSCT is around a month – thus, time 
to cellular recovery following IST or matched UD HSCT can be considered as similar if a 
matched UD can be found quickly. 
This report concludes recommending that if a matched UD can be found quickly, then 
transplantation could be considered as a potential first-line option in children who lack a 
matched sibling donor. The decision should then depend on the preferences of patients, 
physicians and donor availability until further data become available.
38
 
  
    
51 
 
6.3.2 – Immunosuppressive Therapy (IST) 
Several large prospective trials in the United States of America, Europe and Japan showed 
consistent studies establishing the efficacy of IST
37
,  which is recommended to be the first-
line therapy for SAA patients who lack a matched sibling or those who aren’t candidates for 
BMT (due to age or other comorbidities).  
The standard regimen remains horse antithymocyte globulin (h-ATG) plus Cyclosporine A 
(CsA), leading to hematopoietic response rates ranging from 60 to 75%, with children 
reported to achieved response rates of 75%
37
. The probability of survival at 5 years ranges 
from 60 to 85%.
35 
There are several publications describing the attempts to improve the standard regimen 
described above – both as an attempt to improve the response rates achieved, but also as a 
way to prevent the known complications from this therapeutic modality, like relapse or clonal 
evolution (explored further in this section). Amendments included the use of rabbit-ATG 
(which is a more potent immunosuppressant than h-ATG) instead h-ATG, the addition of 
high-dose corticosteroids
9
, mycophenolate mofetil
9
, rapamycin
9
 or sirolimus
37
 to ATG 
regimen, or the use of high dose of Cys (50mg/Kg/d during 4 days). 
Rabbit-ATG (r-ATG), being effective in some patients when used on refractory and relapsed 
settings as a salvage regimen
9 
(see section 6.4), was widely mentioned as possible more 
effective first-line therapy. However,  latest reports including a prospective and randomized 
study at the National Institutes of Health (NIH) concluded that at 6 months, the rate of 
hematologic response was markedly inferior with r-ATG (37%) when compared with h-ATG 
(68%). The difference in response rate resulted in a significant survival difference, with 70% 
of patients alive at 3 years after rabbit ATG compared with 94% with horse ATG. 
37  
    
52 
 
The addition of others 
immunosuppressants (like 
mycophenolate mofetil or 
sirolimus) have not improved 
the outcomes of ATG
37
, and in 
a 2013 report
9
, Young states 
that neither regimen was able 
to prevents relapse or clonal 
evolution. High dose Cys is 
reported to be used at some 
institutions, but had not been 
broadly accepted since it is 
associated with prolonged 
neutropenia and early mortality 
due to infection when 
compared with the ATG plus CsA regimen
9
.   
This results, and the consideration that despite the use of different h-ATG preparations in 
different institutions, the rates, time course, and patterns of hematologic recovery have been 
reported as consistent across studies, leaded to the acceptance of  h-ATG plus CsA as the first 
IST choice.  
Even that the therapeutic protocols for immunosuppression may vary, there are some key 
recommendations that apparent to be worldwide accepted and commonly used – these are 
described on table 8. 
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6.3.2.1- Management after IST 
IST and its efficiency can be evaluated based on the response rates – and to allow the 
comparison between several cases, there are also criteria pre-defined for this classification, 
which were approved in 2000. These are presented in table 9. 
 
 
 
 
 
 
 
 
Responses are recommended to be confirmed by two or more blood counts at least 4 weeks 
apart, and should ideally be measured in patients who are not receiving hematopoietic growth 
factors.
40
 Hematologic improvement is reported to not expected for 2-3 months after ATG, 
with the majority (90%) of responses described to be occurring within the first 3 months, and 
with fewer reported to occur between 3-6 months or after
24
. 
 
6.3.2.2 - Responder’s patients 
It is common practice tapering CsA after response - however, there’s still some controversy  
about the best approach. Possible strategies identified may include a CsA tapper at 6 months 
among responders
 24
 or given for a minimum of 12 months
32
. Either way, it is widely know 
that there is a significant risk of relapse with rapid tapering of CsA
13
, therefore a very slow 
tapper is highly recommended. 
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There’s also reference in some reports about the possibility of some patients being CsA 
dependent – these appear to need a low dose for a long period of time, being also mentioned 
the possibility of becoming impossible to stop the CsA completely.
32 
Fluctuations in blood counts are reported to be frequent in the weeks after IST, and an over-
flow of blood counts analysis is not recommended. It is proposed that these procedures should 
be adapted to the criteria for response (e.g. assessment at 3 and 6 months)
24
. Continued 
improvement of blood counts occurring over years
24
 is also described and reported. 
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6.4 - Refractory Patients and Salvage Therapies 
Refractory patients had been defined in literature as those cases that 6 months after one course 
of the standard regimen of IST still present blood counts fulfilling the SAA criteria – thus, 
there is a lack of response, with persistence of severe pancytopenia.
24
 
A 2013 review by Marsh & Kulasekararaj
41
 is a particular informative publication about the 
treatment options currently available for these patients. The authors start by highly 
recommend that in these cases and before considering any other therapeutic options, some 
issues must be clarified: first, IAA diagnosis must be reassessed – this includes both exclusion 
of a hypocellular MDS and also CAA that may be unnoticed at initial presentation. The same 
review also points some factors that could lead to the lack of response to initial IST, raising 
the hypothesis that the pathogenic mechanism may not be immune mediated in this cases 
(representing a CAA case and/or telomere disease) or, that there may be a situation of extreme 
hematopoietic stem cell exhaustion (being this finding consistent with the results reported in 
other publications, stating that a third treatment with IST, with the previous two ineffective, is 
invariable useless in SAA).
41
 
Even that there’s no preferential strategy defined, considering the 2013 review cited and also 
several other recent publications it is possible to underline some assumptions: first, it is 
recommended that the first option should rely on HSCT – both sibling BMT if the patient is 
older than 40 years (or 50), or UD. The last option, reserved for younger patients, as seen in 
section 6.3.1, is already a matter of controversy, with a possibly role of a UD HSCT even as 
first line therapy, instead a first course of IST.  
In this concrete question there is a reported unquestionable benefit with UD BMT over a 
second course of IST – even that the 5-year overall survival was reported as being similar in 
both strategies, failure-free survival is reported to be significantly higher in the patients 
    
56 
 
submitted to transplantation. Marsh & Kulasekararaj (2013) reported rates reaching 84% in a 
Japan study, against 9% from those receiving a second IST course.
41
 
The unavailability of a suitable matched donor is not infrequent – and it is directly related 
with the main difficulty reported in the management of this cases. Treatment options are 
described as strategies which may include a repeat course of ATG, the use of other agents, 
immunosuppressive or not, and, nowadays, also a possible alternative donor transplantation 
(cord blood transplantation or haploidentical HSCT). 
A repeated course of ATG, using r-ATG instead of h-ATG is the most reported and used 
approach to refractory SAA - Marsh & Kulasekararaj (2013) made reference to response rates 
between 22% to 77%.
41
 The authors also refer other options like ALZ, which is a humanized 
anti-CD52 IgG1 monoclonal antibody used currently in autoimmune cytopenias, allogeneic 
HSCT conditioning, pure RBC aplasia, and had been also reported and used as a possible 
salvage therapy of refractory SAA. The response rates and OS are apparently comparable to 
those obtained with a r-ATG plus CsA regimen, with the advantage of being one CsA free 
regimen, making it as a possible option for patients with comorbidities that could increase the 
toxicity of a CsA regimen, or those who experienced poor tolerability to CsA before.
36,41
  
High dose Cys, has been used as a first line therapy for SAA in some centers, but, as 
mentioned, is also associated with early mortality, and therefore, not recommended. 
Therefore, the same 2013 review recommends that at a refractory SAA setting, the use of Cys 
should be restricted to clinical trials, considering the currently existence of less toxic drugs.
41
 
On example of these drugs also mentioned is Eltrombopag, which is an oral thrombopoietin 
mimetic reported as one inductor for platelet maturation and release by binding to c-MPL 
receptors on megakaryocytes.
41
 It is been widely mentioned on recent literature due to the 
results of recent studies where trilineage responses were identified in 24% of studied patients 
41
. In other publication by Young in 2013, the author reported results from a pilot study where 
    
57 
 
more than 40% of AA refractory patients from two dozen evaluated had shown response with 
a normal cellularity also found in BM at 9 to 12 months – this finding is also characterized by 
the author as being unusual even after successful IST.
9
 There’s still no prospective clinical 
trials about the safety and efficacy of eltrombopag, but the hypothesis that this agent can also 
have a role as a first line therapy along with ATG plus CsA has arisen in several 
publications
9,41
.  
For last, androgens are also mentioned in the 2013 review
41
 by Marsh & Kulasekararaj – and 
are reported to induce responses in patients with telomeropathies who manifest as apparent 
AAA due to increased telomerase activity via aromatization of estradiol to steroids.
41 
However, this agents had lacked efficacy in early randomized studies when combined with 
ATG, but some centers report to offer a trial of androgen therapy for 3 months to patients who 
are refractory to IST and lack good HSCT options.
24 
Alternative stem cell sources have been a currently area of intense investigation – unrelated 
cord blood transplant is one of the options being studied, and some studies had already been 
reported. Marsh & Kulasekararaj identified the main problem as being engraftment failure, 
with a cumulative incidence of neutrophil recovery of 51% at 2 months and a 3 year overall 
survival.
41
 The optimal conditioning regimen for this type of transplant is still unknow.
41 
Haploidentical related HSCT is an option that, if successful, allows the possibility of the 
majority of patients having a possible donor, with a short time between diagnosis and 
procedure
41
 - however the authors conclude that results with this option had not shown to be 
effective. 
A promising combination of haploidentical with cord blood cells are also reported in the 
recent reports
37,41
 , with preliminary data showing promising engraftment of the cord unit and 
low rates of GVHD 
37
. Further studies are currently on course. 
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To conclude, supportive care, fundamental at all stages of the disease, assumes at the 
refractory patients a major role, considering the reported longer neutropenia periods at which 
these patients are submitted.  There’s also a significant reduction in deaths from infection in 
the latest years, unquestionably due to the improvements of supportive care in the refractory 
setting. 
 
Figure 3 – Summary of options available for refractory AA patients.   
 
AA- Aplastic Anemia, CAA – Congenital Aplastic Anemia, Cys – cyclophosphamide, HSCT - Hematopoietic Stem Cell 
Transplantation, IST- Immunosuppressive therapy, MDS- Myelodysplastic Syndromes, UD - Unrelated Donor, r-ATG - 
Rabbit Antithymocyte Globulin,  SAA- Severe Aplastic Anemia  
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6.5- Long Term Management 
Long term follow up is a necessity at AA management considering the risk for well 
documented late complications like hematologic relapse or clonal evolution. There isn’t a 
currently defined protocol described for the best strategy - however it is widely recommended 
the assessment of BM morphology and karyotype (Scheinberg & Young
24 
recommended this 
to be done at the 6 and 12 months after treatment followed by a yearly evaluation). 
Literature is pretty consistent - the finding of a hypocellular BM should not be linked with 
refractory AA, or even relapse, if blood counts improvement had occurred. Marrow cellularity 
does not correlate with blood counts, and this last it’s recommend as the parameter to guide 
management.
24 
 
6.5.1 - Relapse 
There isn’t a defined concept of relapse - Scheinberg & Young24 defined this as those cases 
when reintroduction of IST is required for decreasing blood counts. The authors also state that 
this usually occur within 2 to 4 years of IST. 
It is also mentioned as being necessary the confirmation of a trend, and not a single blood 
count, since oscillating numbers can occur normally, and most patients are reported to 
respond to further immunosuppression.   
Relapse is recommended to be treated with reintroduction (or dose increase) of CsA for 2 to 3 
months, and if CsA alone is ineffective, a second course of r-ATG/CsA is reported to yield 
responses in approximately 50% to 60% of cases.
24
 ALZ monotherapy is also an option 
mentioned in several publications. UD HSCT on first relapse in younger is not recommend, 
due to the positive outcomes of further immunosuppression. Relapse alone has not been 
correlated to worse survival in SAA.
24
 
    
60 
 
6.5.2 - Clonal evolution 
IST and the protocols proposed had result in excellent long-term survival rates, but had also 
lead to the recognition of possible late clonal complications like clonal evolution to 
Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML).  
It was already referred at section 5.3 that 10% of patients with apparent AA by all other 
criteria may have clonal chromosomal abnormalities – the most frequently observed are 
trisomy 8, trisomy 6, 5q- and anomalies of chromosomes 7 and 13.
29
 
The true meaning of the presence of these findings is still unknown – and in the absence of 
morphological evidence of MDS or AML after thorough review of blood smears and BM 
slides, a diagnosis of AA rather than MDS/AML is usually done by most practices.  
In some of these patients, chromosomal abnormalities are reported to be transient, and may 
even disappear, what is often seen after successful IST.
42
 
Marsh et al guidelines (2009) even recommend that patients who are not BMT candidates and 
have an abnormal cytogenetic clone (except monossomy 7) must be managed in the same way 
as patients who have none.
29
 
Monossomy 7 is reported to be related with a high risk to the evolution of MDS – evolution to 
MDS can occur either early or late in the course of the disease. Afable et al (2011) states that 
some patients who are initially suspected to have IAA may show a rapid progression to AML, 
but the late evolution to MDS is more typical, and usually seen in refractory cases or in those 
who didn’t achieved a full response.42 
MDS evolution is described in the majority of publications as one clinical set where 
worsening blood counts remain unresponsive to immunosuppression, and where it can be 
found prominent dysplastic cells in the BM and also abnormal cytogenetics. On these cases, 
treatment with HSCT is reported as the only potentially curative therapy.
 24
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Afable et al (2011), cited variation rates of the setting of this complication from 1,7% to 57% 
in the observation period of 5 to 11 years.
 
The authors also mentioned that biomarkers able to 
predict MDS evolution are currently not known in AA, but there are data that suggest that 
those AA patients with complete and durable responses to IST are at lower risk of progressing 
to MDS.
42 
As also mentioned in the 6.4 section, in a case of decreasing counts, a BM examination is 
reported as being necessary to rule out the possibility of evolution to MDS and to avoid futile 
therapy with ATG (which is usually ineffective)
42
. 
Literature presents also another conception: true clonal evolution and progression to MDS or 
AML - which includes findings of numerical expansion of clonal cells, and therefore, 
diagnosis of a clonal malignancy - has to be distinguished from pseudoclonality. This concept 
refers to those analyzes of BM samples that reflect findings which had resulted from clonal 
abnormalities often transient and with relative expansion in a contracted stem cell pool.
42
 
PHN evolution is also possible – and this subject was already presented and explored on 
section 3. Even that this correlation with AA is still matter of clear discussion, in many 
aspects PHN evolution can be similar to the evolution of chromosomal abnormalities.
42
 
Pathogenesis of clonal evolution is also unclear and in the 2011 report, Afable et al also 
presented some points over this subject: considering the main pathologic process in AA – the 
contraction of stem cell compartment and the decrease number of available HSC – it is likely 
that at the peak of the disease, hematopoiesis in AA is oligoclonal or even clonal. As seen, 
some patients presents chromosomal abnormalities and/or PHN clones at the initial diagnosis 
of AA - depletion of the stem cell pool may then predispose the recruitment of genetically 
defective hematopoietic clone, mostly if the genetic defect involves survival pathways. Some 
other mechanisms may also exist – the presence of excessive short telomeres may represent a 
risk factor to acquisition of chromosomal damage, and the occurrence of some mutations may 
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also lead to more rapid evolution of cryptic clones and progression to more advanced disease 
(identified mutations are reported to be on TET2, CBL, and DNMT3A[u7] genes in several pos-
AA monossomy 7 patients). At last, authors present the theory already presented at section 2 - 
cytogenetically abnormal cells may trigger an immune response first directed to eliminate 
abnormal cells but also leading to destruction of normal cells
18
 – the following selecting 
pressure would then lead to the generation and escape of mutant clones that would outgrow 
normal hematopoiesis. 
The authors end the article relating the following hypothesis: irrespective of initiating events, 
the expansion of aberrant clones is likely a result from an immune selection, and clonal 
progression may be regarded as a form of immunologic escape.
42 
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Conclusion 
AAA, even being considered a rare hematologic disease, is the target of several research 
works. To current date, incidence is reported as 2,34 cases per million per year on the Western 
countries. There’s no specific data regarding Portugal, so it’s only possible to assume that this 
is also valid for our population. It is also reported and accepted a biphasic distribution and a 
sex ratio of 1:1. 
There’s still plenty difficulties reported to establishment of a clear knowledge about the 
pathological mechanisms of IAA, but several recent publications support the immune system 
role on stem cell depletion already sated by the oldest ones. It is worldwide accepted that this 
disease is most likely an outcome of several results from particular roles concretized by 
different factors. Factors nowadays reported include lymphocytes, cytokines, autoantibodies 
and also some genetic factors like HLA, T cell encoding genes, mutations and polymorphisms 
and telomeres. This last is widely reported and represents now, besides a proven risk factor, a 
probable prognostic indicator. This fact has led to the currently overflow of reports and 
studies concerning telomeres roles on AAA. The reason why T cells are activated, leading to 
the immune attack is still unknown. 
The mechanism responsible for the singular relation with PNH remains also unknown, and 
several hypotheses tested were presented in this document. Literature also states as the most 
acceptable possible mechanism, the fact that PNH cells may have a proliferative advantage 
over non-PNH cells, not by intrinsic growth or survival advantage, but by an immune 
mechanism of selection. Concerning IAA, the true significance of the presence of a PHN 
clone is unclear – and there is also some unconformity between available studies. Some stated 
that the presence of a clone has been reported to be predictive of response to IST, while others 
have not observed this finding. This variation of results should lead to new studies. 
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Diagnosis of IAA, and the investigations required support the peculiarities of this disease – 
clinical symptoms and signs are unspecific and none classical or pathognomic sign is 
reported. Therefore, IAA remains a diagnosis of exclusion. It is also fundamental being 
familiar with the conditions that must be excluded, and which findings or characteristics must 
lead the clinic to assume as unlikely to be related to a case of IAA. Literature is consensual 
that if a thorough investigation is lead, majority of cases will be correctly identified or 
excluded – leading to a correct management of IAA or other conditions. 
After an identified and confirmed IAA case, severity of the disease must be assessed, which 
will then allow the definition of the best treatment/management option. Severity had been 
classified using the Camitta criteria – these criteria are worldwide accepted and are directly 
linked with the treatment management. It is consensual in literature that SAA and VSAA 
patients require treatment, both supportive and definitive. Non-Severe AA cases, in most 
publications and clinical practices are suggested to be kept under observation, especially if 
patients are blood transfusions independents. However some recent data reported a possible 
prejudice in this “watch and wait practice” – and there is an actual need in further controlled 
studies. Camitta criteria by itself are also the target of some reports – these last question the 
validity of the criteria considering the current panorama of clinical practice and the proved 
other variables linked to IAA that may have a significant role on prognosis, and aren’t 
included in the criteria. However, this classification, and the management that its use implies, 
are still the practice recommended on recent guidelines.  
Supportive measures are seen as fundamental in all cases – however these measures alone are 
not definitive therapies and they should not replace definitive therapies if these are indicated. 
It is usual that each institution adopts the protocol to be followed. 
Definitive measures incorporate two modalities: BMT and IST. There’s clear data about the 
primordial choice on sibling BMT if possible - this modality, if succeeded, can be curative, 
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and current approaches allow rates of success with a sibling donor of almost 90%.  
Complications are related with the technique itself, and not with the disease – that means, 
graft failure, acute and chronic GVHD, which can occur with any clinical entity that requires 
BMT as treatment option. The availability of an HLA-matched sibling is the major hurdle to 
this option – which is reported to be around 30%. Considering that, UD and mismatched 
transplants, have almost twice the transplant-related mortality and risk of GVHD as matched 
sibling donor transplants, and also the correlation of increasing age with the risk of GVHD. 
This option is currently recommend and worldwide accepted to be the first line therapy only if 
patient and donor fulfills the criteria required (such as an HLA-matched sibling donor and age 
under 40 years old). However, recent medical advances leads to a new panorama where 
literature mentions a major improvement on the outcomes UD HSCT – factors like more 
stringent donor selection, less toxic and more effective conditioning regimens, and also higher 
quality supportive care are reported to be crucial on this. The positive outcomes of IST still 
directs current guidelines to consider the BMT from UD or mismatched donors as a second 
option reserved for patients who failed to respond to one or more courses of IST, but a 
potential role on the management of younger patients without a sibling donor is already under 
discussion. There’s still no consensus on this matter. 
IST is actually comparable to BMT outcomes. The standard regimen remains horse h-ATG 
plus CsA. Hematopoietic response rates are reported to range from 60 to 75%, with survival 
at 5 years rates from 60 to 85%. 
The current debate sets on what are the options for those patients that don’t achieved a 
complete response after a first IST protocol, the relapsed cases, or how to avoid known 
complications like the clonal evolution. 
Literature focus now in some future goals: a possible improvement in the current IST 
outcomes, with possible addition of others agents to the current first-line scheme, new salvage 
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therapies, and what can be done to prevent possible late clonal complications like clonal 
evolution to MDS and AML.  
The ability to identify patients with a higher probability of hematologic response, relapse, 
clonal evolution and early mortality may allow for a more logical treatment allocation, and 
then, improve or avoid the actual outcomes. 
Optimistic views lead to possible improvements where better knowledge about the 
pathological ways and specific factors could improve the current outcomes – allowing a 
panorama similar with the PHN after the introduction of eculizumab. However, it is largely 
present in the results of recent studies that medical advances concerning IAA may have 
reached a plateau. 
IAA shows the referred singularities that can represent true handicaps on medical 
investigation, e.g. a rare disease, where the potential cells of interest (HSCs) are lacking. 
Evidence-based medicine assumes a major role and prospective studies could lead to more 
concrete information about the best treatment options. However, these last are objected by 
ethical questions: considering the highly positive outcomes with the known therapies, these 
should not be denied to a patient in the set of a possible research of others agents. Other 
factors, like possible different mechanisms on younger patients and older ones, or even 
between the responders and non-responders also represent a major hurdle to the establishment 
of protocols based on proven benefits.  
It is clear that advances in medical care lead to outstanding positive outcomes, comparing the 
past survival rates of 10 to 20% to the actual 80 to 90% - but those, had led to different 
challenges. In the current era of the chronic disease paradigm, the role of IAA patients, the 
long-term management of these, the possible new therapies or options (like new sources for 
HSC for BMT) and the options reserved for those that evolve to clonal conditions still remain 
as questions that not being perfectly defined, still needs to be sorted.    
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